Clinical Trials Logo
  1. Home
  2. Cutaneous Lymphoma
  3. NCT04520529

Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas — LYMPHOTEQ  

Cutaneous Lymphoma Clinical Trial

Official title:
Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas

Clinical Trial Summary

Cutaneous lymphomas are a heterogeneous group of extra-nodal lymphomas. The prognosis of cutaneous lymphomas is extremely variable from one subject to another. In the majority of cases, there is no cure for cutaneous lymphomas. Cutaneous lymphomas primarily affect the skin, and secondarily the blood, lymph nodes and possibly other organs. The discovery of new molecular prognostic factors will allow a better identification of patients at high risk of aggressive evolution and the implementation of a personalized therapeutic strategy. The identification of new therapeutic targets is necessary in order to develop new innovative treatments for cutaneous lymphomas.The primary objective is to identify novel molecular prognostic factors associated with 5-year overall survival in cutaneous lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04520529
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Adèle DE MASSON
Phone 01 42 49 43 19
Email adele.demasson@aphp.fr
Status Not yet recruiting
Phase N/A
Start date September 30, 2020
Completion date September 30, 2050
View Details
See also
  Status Clinical Trial Phase
Completed NCT01902225 - Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Phase 1
Completed NCT00400556 - ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells Phase 1
Active, not recruiting NCT01396070 - Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level N/A
Terminated NCT01556828 - Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing N/A
Terminated NCT01187446 - Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides Phase 1/Phase 2
Recruiting NCT03602157 - Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL Phase 1
Recruiting NCT04670874 - Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
Completed NCT03458117 - T-VEC in Non-melanoma Skin Cancer Phase 1